Confused Biden Says “I Better Not Start The Questions, I’ll Get in Trouble” As Press Shooed Away
President Biden held a meeting of his Competition Council this week to announce his plans to lower costs for families who have been crushed by inflation. Even though he doesn’t seem to know what planet […]
The post Confused Biden Says “I Better Not Start The Questions, I’ll Get in Trouble” As Press Shooed Away appeared first on The People’s Voice.
CNN Spins Conspiracy Theory, Tries To Tie Lawyer To Alex Jones On Jan 6th
Alex Jones covered how CNN is using a pro-Trump attorney’s selfie taken at the Capitol on January 6th, with him in the background, as ‘proof’ of a crime.
“Chesebro goes, challenges the election in Georgia, it’s all come out it was stolen,” Jones said. “They want to intimidate you that you can’t say that.”
Jones further explained how CNN twisted how the attorney is a criminal because he’s a Trump supporter.
Don’t miss:
EXCLUSIVE: Economist Who Warned Of Regional Bank Runs Makes Chilling New Predictions
California Man First to be Charged With Smuggling Greenhouse Gases Into US
A San Diego man was arrested Monday for smuggling greenhouse gasses into the United States from Mexico.
Federal prosecutors say this is the first criminal case of its kind in the country.
The indictment alleges Michael Hart, 58, imported hydrofluorocarbons (HFCs) – a chemical compound commonly used for refrigeration, air-conditioning and aerosols – from Mexico and then sold them for a profit, which violates regulations created in 2020 ostensibly intended to “slow climate change.”
“This is the first prosecution in the United States to include charges related to the American Innovation and Manufacturing Act of 2020 (AIM Act),” said a press release from the Southern District of California. “The AIM Act prohibits the importation of HFCs, commonly used as refrigerants, without allowances issued by the Environmental Protection Agency (EPA).”
“This office is at the forefront of environmental prosecutions, and today is a significant milestone for our country,” said U.S. Attorney Tara McGrath. “This is the first time the Department of Justice is prosecuting someone for illegally importing greenhouse gases, and it will not be the last.”
“We are using every means possible to protect our planet from the harm caused by toxic pollutants, including bringing criminal charges.”
“Hart faces 13 separate charges, including conspiracy, importation contrary to law, multiple counts of selling imported merchandise contrary to law and criminal forfeiture,” reports CBS. “He could face decades in prison if convicted on any one of the charges related to illegal importation”
Read the entire press release HERE.
Watch: Democratic Leaders Tell America That Illegal Aliens Come First
34 Deaths, 302 Serious Injuries: RSV Vaccines Aren’t Even a Year Old but Some Experts Say It’s Time to Pull Them From the Market
It’s been less than a year since the Centers for Disease Control and Prevention (CDC) recommended two new respiratory syncytial virus (RSV) vaccines — yet CDC data and the Vaccine Adverse Event Reporting System (VAERS) already show reports of 34 deaths, 302 serious adverse events and according to news reports this week, a safety signal for Guillain-Barré syndrome (GBS).
Reported cases include several instances of severe adverse events in newborns, including the death of a 27-day-old baby who was wrongly administered the vaccine, and in pregnant women and people in age groups for which the RSV vaccines were not approved.
The U.S. Food and Drug Administration (FDA) approved Pfizer’s Abrysvo and GSK’s Arexvy RSV vaccines for adults ages 60 and older — but not for children or babies.
Abrysvo is also approved for pregnant women, targeting RSV prevention in babies. The FDA approved Abrysvo and Arexvy in May 2023.
According to CDC data, approximately 9.65 million RSV vaccine doses — 6.58 million Arexvy doses and 3.06 million Abrysvo doses — were administered as of Feb. 16.
Members of the CDC’s Advisory Committee on Immunization Practices (ACIP) presented the data on deaths and adverse events related to the RSV vaccines at a Feb. 29 meeting.
Yet, ACIP — and news media reports — primarily focused on GBS safety signals, glossing over deaths and the administration of the vaccines to unauthorized age groups.
Instead, CDC officials claimed it’s too early to determine if the RSV vaccines caused the adverse events and reiterated that the shots are safe, according to The Associated Press (AP).
Experts who spoke with The Defender disputed the CDC’s reassurances. Brian Hooker, Ph.D., chief scientific officer for Children’s Health Defense (CHD), said “34 deaths in 10 months should be sufficient to pull the RSV vaccines from the market. But the FDA will not do that — nor will there be full investigations regarding these deaths.”
“I am greatly concerned with the excessive application of the RSV vaccine,” said cardiologist Dr. Peter McCullough. “We are beginning to see the tip of the iceberg in terms of serious side effects.” “The Wuhan Cover-Up” by Robert F. Kennedy Jr. Order Now
CDC creating ‘illusion of safe and effective’
According to the CDC data presented at the Feb. 29 ACIP meeting, of the 34 deaths reported as of Feb. 16 following RSV vaccination, 22 were linked to Arexvy and nine to Abrysvo. In three instances, the report listed “no brand name.”
Yet, discrepancies in the data are evident, as the public-facing VAERS database indicates only 29 RSV vaccine-related deaths as of Feb. 23. And according to Albert Benavides, founder of VAERSAware.com, three more “hidden” deaths reported after RSV vaccines are listed in VAERS, but the vaccine name is unlabeled.
Benavides, who identified discrepancies and contradictions in VAERS data and has called attention to the existence of two parallel VAERS databases — one that is public-facing and one that is not — said, “It is simply gross and despicable the CDC and FDA are allowed to pass off this data obfuscation as pharmacovigilance.”
He added: “VAERS administration is simply not publishing all legitimate reports received.”
One of the deaths recorded in VAERS involved a 27-day-old baby from New York — even though the RSV vaccines are not approved for children. According to the report, which was entered into the VAERS database on Jan. 8, the newborn was vaccinated at a doctor’s office “and he passed away right there.” The date of death was unspecified.
Other RSV vaccine-related death reports included:
- A report involving a foreign woman of “unknown” age but who was pregnant. She received Abrysvo Dec. 27, 2023, and died Jan. 1, 2024.
- A 67-year-old New Jersey man who received Arexvy Oct. 14, 2023, and died two days later — a death acknowledged by GSK as “related to Arexvy.”
- A 69-year-old Florida man who received Arexvy concurrently with the Pfizer COVID-19 vaccine Sept. 28, 2023, and died two days later. According to the VAERS report, an EKG on the date of his death was “grossly ‘abnormal’” despite no known cardiac history and an “unremarkable” cardiac exam two months prior.
- A 70-year-old California man who received Arexvy concurrently with a flu vaccine on Sept. 5, 2023. Increased coughing and fever began “less than 24 hours later” and lasted for four days, until “the patient was found deceased at home.”
- A 73-year-old Virginia male who received Arexvy Jan. 24 and was diagnosed with GBS. Symptoms began 11 days after vaccination. He died Feb. 15.
- A 75-year-old Virginia woman who received Arexvy Jan. 4, died two hours later.
- A 76-year-old Michigan man who received Arexvy Jan. 11, sustained tachycardia and difficulty breathing, and died of acute sepsis and pneumonia Jan. 15.
- A 77-year-old Pennsylvania man who received Arexvy Jan. 4 and soon experienced “seizure-like activity” despite no history of seizures. He died Jan. 6.
- An 81-year-old California man who received Arexvy and a flu vaccine Sept. 18, 2023. He sustained severe cardiopulmonary arrest and died five hours later.
- An 81-year-old New Mexico woman who received Arexvy concurrently with the Moderna COVID-19 vaccine, and pneumonia, adenovirus and flu vaccines, on Oct. 19, 2023. On Oct. 29, 2023, she sustained a hemorrhage and later died.
- An 85-year-old Colorado man who received Abrysvo and a flu vaccine on Sept. 11, 2023. Two days later, he “developed symptoms of shingles in his eye” and later “developed meningitis/encephalitis that led to a host of other complications that ultimately led to his death” on Dec. 21, 2023.
According to Benavides, other deaths likely related to RSV vaccination are “hidden” within VAERS, with details such as the vaccine name listed as “unknown” in some reports.
This includes the Jan. 8 death of a preterm newborn in Texas. According to VAERS, the baby was “not breathing” hours after vaccination and subsequently died. The vaccine lot number listed in the VAERS report corresponds with Abrysvo.
Benavides said mislabeled reports hide the true extent of adverse events:
“Not publishing legitimate reports is one of their Vegas tricks. They delete legitimate reports after publication, purposely delay published reports, allow reports to be published without critical data fields like age, date of vaccination or death, even when reports are properly documented in the summary narrative.
“It’s not a stretch to believe VAERS administration is systematically and actively scrubbing data fields that were present on initial submission to create the illusion of ‘safe and effective.’”
Two other RSV vaccine-related reports in VAERS list Beyfortus — a monoclonal antibody for RSV administered to babies — in the write-up.
These reports include a male born prematurely in New York who received Beyfortus and the hepatitis B vaccine at birth, and died of “fluid buildup in the lungs.” Another report lists an Arkansas male of “unknown” age who died of cardiac arrest on Feb. 14, although this was deemed unrelated to the “Beyfortus vaccine received” the prior day.
Although Beyfortus is not a vaccine, it is classified as such in some instances. The ACIP recommended adding Beyfortus to the childhood vaccine schedule — giving it a liability waiver — but excluding it from the National Vaccine Injury Compensation Program (VICP). RFK Jr. and Brian Hooker’s New Book: “Vax-Unvax” Order Now
‘Startling’ number of Guillain-Barré cases following RSV vaccination
VAERS lists 3,834 adverse events relating to the RSV vaccines as of Feb. 23, with approximately two-thirds of the reports pertaining to Arexvy. A total of 302 reports are classified as serious adverse events, with slightly over half connected to Arexvy.
Yet, the ACIP meeting and subsequent news stories largely focused on a single safety signal: a higher-than-normal incidence of GBS in RSV vaccine recipients.
According to The New York Times, GBS causes the immune system to attack the nerves, leading to paralysis and death in severe cases. According to AP, “An estimated 3,000 to 6,000 people develop G.B.S. in the U.S. each year,” mostly older adults.
“Rare cases of Guillain-Barré syndrome have been linked to other vaccines, including those against influenza and shingles,” the Times reported. The Times did not mention incidences of GBS connected to COVID-19 vaccination.
AP reported that health officials estimate “About two cases of Guillain-Barré might be seen in every 1 million people who receive a vaccine.” CDC data indicate the GBS incidence rate for Abrysvo recipients was 4.6 cases per million people.
GBS incidences were lower for Arexvy, but according to AP, officials are also performing “follow-up tracking” in people who received this particular vaccine.
“These data suggest a potential increased risk” from the RSV vaccine, said Dr. Tom Shimabukuro, director of CDC’s Immunization Safety Office, in remarks quoted by AP.
“Given that the RSV vaccine was first approved in the U.S. on May 3, 2023, the number of VAERS reports for GBS, death and atrial fibrillation are indeed startling,” Hooker said.
According to VAERS, 34 GBS cases related to RSV vaccination were recorded. Most were in the 65-79 age group, but at least two cases were reported in people under age 60, even though the RSV vaccines are not approved for those age groups. CDC data presented at the Feb. 29 ACIP meeting said 23 GBS reports have been “verified.”
From these “verified” reports, 15 involved Abrysvo, 14 patients were male, seven received a COVID-19 vaccine at the same time they received the RSV shot, the median age was 71 and one patient died.
The ACIP presentation referred to one GBS report “in a non-pregnant female patient aged 50s years” who received Abyrsvo. VAERS includes reports of other GBS cases in patients in age groups not authorized to receive the RSV vaccines.
In one instance, a 6-month-old girl from California received Abrysvo and several other vaccines at a military site on Nov. 30, 2023. She sustained “life threatening” cardiac arrest. The RSV vaccine “was given by mistake,” according to her VAERS report.
And a 28-year-old Kentucky female who received Abrysvo on Dec. 1, 2023, soon developed “facial weakness,” despite “no history of similar symptoms.” She was hospitalized for seven days and diagnosed with GBS.
The ACIP also referenced 58 cases of atrial fibrillation, three cases of acute disseminated encephalomyelitis, two cases of transverse myelitis and one case of posterior reversible encephalopathy syndrome and acute encephalitis following RSV vaccination. Your support helps fund this work, and CHD’s related advocacy, education and scientific research. Donate Now
Risks of RSV vaccines evident during clinical trials
Despite the deaths and safety signals connected to the RSV vaccines, CDC officials at the Feb. 29 ACIP meeting adopted a reassuring tone regarding the vaccines’ safety.
“Due to the uncertainties and limitations, these early data cannot establish if there is an increased risk for GBS after vaccination,” Shimabukuro said, according to the Times.
According to AP, “CDC officials also presented estimates that the vaccines have prevented thousands of hospitalizations and hundreds of deaths from RSV, and that current data indicates the benefits of vaccination outweigh the possible risks.”
“R.S.V. vaccines may prevent an estimated 120 to 140 in-hospital deaths and about 25,000 outpatient visits per million doses administered,” the Times reported.
“Pfizer is committed to the continuous monitoring and evaluation of the safety of Abrysvo” and is conducting four safety studies examining the risk of GBS, said Reema Mehta, Pfizer’s vice president of risk assessment and safety, in remarks quoted by AP.
“There are limitations to all of these data, and further analysis by FDA, CDC and the vaccine manufacturers are needed to confirm and quantify any potential risk,” said Alison Hunt, a GSK spokesperson, in remarks quoted by the Times.
Experts noted the contradiction of CDC officials identifying safety signals from VAERS, after a Feb. 15 U.S. House of Representatives hearing where CDC and FDA officials downplayed the role of VAERS in the detection of safety signals.
Dr. Daniel Jernigan, director of the CDC’s National Center for Emerging and Zoonotic Infectious Diseases, claimed at the hearing that VAERS is “not intended to determine if a vaccine is causing an adverse event.”
Saying that such criticisms were “a ploy to remove emphasis” from adverse events, Hooker said, “VAERS inaccuracies are only in under-reporting, not misreporting.”
“The [2011] Lazarus study conducted at the request of CDC shows that perhaps 1% of all vaccine adverse events are captured by VAERS and that the true vaccine adverse event rate is around 1 in 39,” he said.
According to Dr. Meryl Nass, an internist and biological warfare expert, “The FDA and CDC have enormous amounts of data on well over 100 million Americans” but “refuse to study the data.”
According to AP, public health officials were aware of GBS instances identified during clinical trials and “different systems were watching for signs of problems.”
Nass said there is little evidence that RSV vaccines are saving lives in either babies or the elderly.” But, she said, “There was good evidence, even in the pre-marketing data, that the RSV vaccines caused neurologic complications, including GBS.”
“Why would anyone take an RSV vaccine that has a reasonable chance of causing a neurologic illness to prevent colds? The answer is that they are not being told the truth,” Nass said, calling for RSV vaccines to not be licensed or used until their safety is proven.
McCullough said RSV “is like a mild cold and easily treated at home. He said the risk of “fatal paralysis, cardiac side effects and vaccine death far outweigh the occasional case of RSV, which we have been managing for many years in internal medicine.”
“I do not recommend the new RSV vaccine to older adults,” he said.
Russia & China Plan Building Lunar Nuclear Power Plant on Moon
Russia and China are mulling jointly building a lunar nuclear power plant, Yuri Borisov, the head of Russia’s space agency Roscosmos, said on Tuesday.
“Today we are seriously considering a project … somewhere at the turn of 2033-2035 … to deliver and install a power unit on the lunar surface together with our Chinese colleagues,” Borisov said during a lecture at the World Youth Festival.
Harnessing the power of “nuclear space energy” could allow lunar settlements to be built, as solar panels would not be able to provide enough electricity to power such bases, he pointed out
“This is a very serious challenge… it should be done in an automated mode, without the presence of humans,” Borisov added, hoping that robots could be up to the task.
According to the Russian Federal Space Agency head, the technology required for the construction of such a lunar nuclear power plant is almost ready. Furthermore, Borisov weighed in on Russia’s plans to build a nuclear-powered cargo spaceship called Zevs (Zeus).
“We are working on a space tugboat… that would be able, thanks to a nuclear reactor and high-power turbines … to transport large cargoes from one orbit to another, collect space debris and engage in many other tasks,” Borisov said.
He added that one tricky aspect of this is to find a solution for how to cool the nuclear reactor.Last year, Borisov had described how the nuclear space tug could be used to push inactive geostationary satellites into deep space, adding, “We must think about our future use of outer space, and ensure that it is environmentally clean for future generations.” On Tuesday, the director general of Roscosmos reiterated that Russia is against the deployment of nuclear weapons in space.
“Of course, space should be free of nuclear weapons,” Borisov said.
Borisov’s remarks echo what President Vladimir Putin said a few days ago. Russia does not plan to deploy nuclear weapons in space, Putin said at a meeting with the country’s Security Council members on March 1.
“We have already discussed false allegations that are currently being made by some Western officials about our supposed plans to deploy nuclear weapons in space,” the Russian president said.
However, he added that it was essential for the Russian government to monitor the issue to be ready to address any such threats that may emerge from other sides in this domain.Earlier, in his annual State of the Nation address on February 29, Putin weighed in on the media craze stemming from unfounded claims of a Russian nuclear space weapon.The Russian head of state called the claims “unfounded” and “fake narratives” designed by the West. Having dismissed these baseless allegations, Putin mentioned that Russia is yet to receive any serious proposals from the US to initiate bilateral contacts on strategic stability.Russian Defense Minister Sergei Shoigu also weighed in, saying that, “Firstly, there are no such projects – nuclear weapons in space. Secondly, the United States knows that this does not exist.”
Joint Moon Base
Russia’s state space corporation, Roscosmos, and China’s National Space Administration (CNSA) concluded an agreement on a joint Moon base project in November 2022, pledging to work together to build a base there by the 2030s. The project is to be implemented in three stages.
Stage 1 stipulates Russian and Chinese lunar missions exploring the Moon together, determining the best location for the lunar station. At this stage, the Russian side is reportedly planning to utilize the Luna-Glob lander.
The second stage envisages establishing a control center for the lunar base, delivery of bulk cargo to Earth’s satellite, and setting up orbital modules for supply of power, communications, and provision of transport services.
The third stage involves the exploration of the Moon’s surface, expanding the functionality of the lunar station modules.
With China’s space projects on the rise in the past few years, the head of the country’s lunar exploration effort, Wu Weiren, an academician of the Chinese Academy of Engineering and chief designer of the Chang’e program, revealed in 2022 that China was working on a new type of nuclear power plant to be used to support a permanent base on the Moon. “We are currently developing a new energy system where nuclear energy can provide high-power and long-time supply. And the communication facility can achieve communication between the Moon and the Earth, or with other planets such as Mars,” Wu said.Reports have suggested the plant would be able to produce one megawatt of power, which is about 100 times more than the one-kilowatt reactor the US space agency NASA plans to generate with its own lunar nuclear reactor.
EXCLUSIVE: Economist Who Warned Of Regional Bank Runs Makes Chilling New Predictions
Worldwide Decline of Freedom Outweighs Improvements
Democratic watchdog organization Freedom House has released its annual ranking of the world’s most free and most suppressed nations.
As Statista’s Katharina Buchholz details below, the report is considered a key barometer for global democracy and this year’s edition found that global freedom has declined for the 18th year straight.
While 2022 had been heralded as a “possible turning point” as about as many countries showed improvements as marked declines, 2023 saw a new low of nations bettering their freedom prospects – only 21.
This number stands opposite 52 countries where political freedoms and civil liberties declined.
The report mentions Ecuador as an example of a country where elections were impacted negatively and downgraded the nation from designated as “free” to receiving the “partially free” label. In the South American country, criminal organizations had killed officials and candidates ahead of the general election that took place in August. In other countries it was incumbents who hindered the access of the population to a free election last year, including in Cambodia, Guatemala, Poland, Turkey and Zimbabwe.
Despite Thailand’s military Senate continuing to yield much power over the country’s legislative bodies, a more competitive election that saw a progressive party finish first earned Thailand a “partially free” designation, up from “not free”. Other nations improving their score were Fiji, Nepal, Liberia and Mauritania.
A total of 195 countries and 15 territories were analyzed on their levels of access to political rights and civil liberties, before being categorized as either “free”, “partly free” or “not free”. While democracy has been in decline for nearly two decades, the global landscape has improved since the report was first published 51 years ago. Back then, 44 out of 148 countries were counted as “free”, versus 83 out of 195 today.
EXCLUSIVE: Economist Who Warned Of Regional Bank Runs Makes Chilling New Predictions